EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cardiac Involvement in Myotonic Dystrophy Type 1: Mechanisms, Clinical Perspectives, and Emerging Therapeutic Strategies

Vamsi Krishna Murthy Ginjupalli iD, Jean-Baptiste Reisqs, Michael Cupelli, Mohamed Chahine iD, Mohamed Boutjdir

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262210992 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Vamsi Krishna Murthy Ginjupalli und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Research Program, VA New York Harbor Healthcare System, New York, NY 11209, USA. Hauptthemen laut MEDLINE: Myotonic Dystrophy, Heart Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 188 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Defense, NHLBI NIH HHS, CIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myotonic Dystrophy Type 1 (DM1) is a complex multisystemic genetic disorder caused by CTG repeat expansions in the DMPK gene, leading to RNA toxicity and widespread splicing defects. These splicing abnormalities affect multiple systems, including the respiratory, skeletal, cardiac, nervous, and endocrine systems, resulting in aggressive symptoms that significantly impact quality of life and survival. Cardiac complications are the second leading cause of deaths in DM1, after respiratory insufficiency. Current research is largely focused on understanding cardiac pathology in DM1. This review highlights recent advancements in the clinical and pathological characterization of DM1 cardiac involvement, preclinical models used to study cardiac dysfunction, and emerging therapeutic strategies that target the molecular basis of DM1. Promising approaches include RNA-targeting strategies such as antisense oligonucleotides (ASOs), gene-editing tools like CRISPR-Cas9, and small molecules that modulate RNA splicing. ASOs aim to reduce toxic RNA accumulation, CRISPR-based approaches aim to excise or correct the expanded CTG repeats, and repurposed small-molecule drugs, such as vorinostat, tideglusib, and metformin, could serve as potential therapeutic agents for DM1 patients with cardiac complications. Despite this progress, several challenges remain: the heterogeneity of cardiac manifestations, unpredictable and often silent progression of arrhythmias, limited therapeutic options beyond implantable cardioverter-defibrillator (ICD)/pacemaker implantations, and complex interplay with the multisystemic nature of DM1. More research and well-designed clinical trials are urgently needed to translate these promising strategies into effective treatments for DM1-associated cardiac disease. Here, we discuss the current knowledge in DM1 cardiac pathology and preclinical models as well as the benefits and pitfalls of the available therapeutic approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myotonic DystrophyHeart DiseasesHumansAnimalsOligonucleotides, AntisenseTrinucleotide Repeat ExpansionGene EditingRNA SplicingMyotonin-Protein Kinase

Stichwörter der Autor:innen

arrhythmiascardiac conduction defectscardiac dysfunctioncardiac electrophysiologymyotonic dystrophy type 1preclinical modelstherapeutic pipeline

Substanzen

Oligonucleotides, AntisenseMyotonin-Protein Kinase

Autor:innen und Institutionen

  • Cardiovascular Research Program, VA New York Harbor Healthcare System, New York, NY 11209, USA.
  • Department of Medicine, Faculty of Medicine, Université Laval, Quebec City, QC G1V 0A6, Canada.
  • CERVO Research Center, Institut Universitaire en Santé Mentale de Québec, Quebec City, QC G1J 2G3, Canada.
  • Departments of Medicine, Cell Biology and Pharmacology, State University of New York Downstate Health Sciences University, New York, NY 11203, USA.
  • Department of Medicine, Cardiology Division, New York University Grossman School of Medicine, New York, NY 10016, USA.

ORCID-Profile: Vamsi Krishna Murthy Ginjupalli, Mohamed Chahine

Förderung

  • Department of Defense
  • NHLBI NIH HHS
  • CIHR
  • US Department of Defense
  • Biomedical Laboratory Research and Development Service of Veterans Affairs Office of Research and Development
  • National Heart, Lung, and Blood Institute
  • U.S. Department of Defense
  • Canadian Institutes of Health Research

Zitieren

APA

Ginjupalli, V. K. M., Reisqs, J. B., Cupelli, M., Chahine, M., & Boutjdir, M. (2025). Cardiac Involvement in Myotonic Dystrophy Type 1: Mechanisms, Clinical Perspectives, and Emerging Therapeutic Strategies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262210992

Vancouver

Ginjupalli VKM, Reisqs JB, Cupelli M, Chahine M, Boutjdir M. Cardiac Involvement in Myotonic Dystrophy Type 1: Mechanisms, Clinical Perspectives, and Emerging Therapeutic Strategies. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262210992

BibTeX
@article{Ginjupalli2025,
  author = {Ginjupalli, Vamsi Krishna Murthy and Reisqs, Jean-Baptiste and Cupelli, Michael and Chahine, Mohamed and Boutjdir, Mohamed},
  title = {Cardiac Involvement in Myotonic Dystrophy Type 1: Mechanisms, Clinical Perspectives, and Emerging Therapeutic Strategies},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262210992}
}
Kostenlos starten →